MedTrace Logo

Stem Cells for Bronchopulmonary Dysplasia

NCT03378063 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2023-05-01

No results posted yet for this study

Summary

Very preterm infants are at high risk to develop to bronchopulmonary dysplasia (BPD) for the lack of effective measures to prevent or ameliorate this common and serious disorder. BPD remains a major cause of mortality and lifelong morbidity in preterm infants

Conditions

  • Bronchopulmonary Dysplasia

Interventions

DRUG

transplantation of mesenchymal stem cell

allogeneic human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation will be given to preterm infants

DRUG

no transplantation of mesenchymal stem cell

MSC transplantation will be not given to preterm infants

Sponsors & Collaborators

  • Children's Hospital of Chongqing Medical University

    collaborator OTHER

  • Chongqing Maternal and Child Health Hospital

    collaborator OTHER

  • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Month
Max Age
3 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2022-12-30
Completion
2022-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03378063 on ClinicalTrials.gov